Ricevi le ultime notizie sulle azioni Theravance Biopharma con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di TBPH

Ultime notizie per

Theravance Biopharma

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Theravance Biopharma, Inc. - Ordinary Shares

Theravance Biopharma Inc

Earnings

Press Releases

Theravance Biopharma, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update

Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress

Theravance Biopharma to Participate in an Upcoming Investor Conference

Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million

Theravance Biopharma Announces Approval of YUPELRI® (revefenacin) by China's NMPA

Theravance Biopharma to Report Second Quarter 2025 Financial Results on August 12, 2025

Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple System Atrophy

Theravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference

TBPH

Alumis

Aquestive Therapeutics, Inc. - Common Stock

Aquestive Therapeutics

Arvinas

Canopy Growth Corporation - Common Shares

Canopy Growth

Collegium Pharmaceutical, Inc. - Common Stock

Collegium Pharmaceutical

Cormedix

Cronos Group

Evolus

Esperion Therapeutics, Inc. - Common Stock

Esperion Therapeutics

Eton Pharmaceuticals, Inc. - Common Stock

Eton Pharmaceuticals

EyePoint Pharmaceuticals, Inc. - Common Stock

EyePoint Pharmaceuticals

Fulcrum Therapeutics, Inc. - Common Stock

Fulcrum Therapeutics

GH Research

Innoviva

MBX Biosciences

Mind Medicine (MindMed) Inc. - Common Shares

Mind Medicine

Oculis Holding

Pacira BioSciences

Phathom Pharmaceuticals, Inc. - Common Stock

Phathom Pharmaceuticals

Septerna

SIGA Technologies

SNDL

Terns Pharmaceuticals, Inc. - Common Stock

Comments

Theravance Biopharma Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO